To the full analysis
Buyback calculator for Chugai Pharmaceutical
Chugai Pharmaceutical stock: key metrics
4519.TChugai Pharmaceutical had an operating margin of 46.9% and a return on invested capital (ROIC) of 43.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 58.5% | 17.9% | 11.8% |
| 2007 | 59.5% | 19.3% | 11.6% |
| 2008 | 60.4% | 15.8% | 12.0% |
| 2009 | 55.0% | 19.3% | 13.2% |
| 2010 | 57.2% | 17.5% | 10.9% |
| 2011 | 57.8% | 16.7% | 9.4% |
| 2012 | 56.6% | 19.5% | 12.5% |
| 2013 | 55.9% | 19.0% | 12.0% |
| 2014 | 52.9% | 16.9% | 11.1% |
| 2015 | 51.8% | 17.8% | 12.3% |
| 2016 | 49.5% | 16.1% | 10.9% |
| 2017 | 52.3% | 19.3% | 13.6% |
| 2018 | 54.5% | 22.3% | 16.0% |
| 2019 | 61.2% | 31.3% | 23.0% |
| 2020 | 65.0% | 39.0% | 27.3% |
| 2021 | 66.0% | 43.4% | 30.3% |
| 2022 | 62.2% | 42.4% | 29.7% |
| 2023 | 62.4% | 37.4% | 29.3% |
| 2024 | 71.0% | 46.5% | 33.1% |
| 2025 | 71.1% | 46.9% | 34.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 9.9% | 15.4% | 8.3% |
| 2007 | 10.4% | 17.2% | 8.7% |
| 2008 | 9.9% | 12.9% | 8.2% |
| 2009 | 13.1% | 19.7% | 10.5% |
| 2010 | 9.2% | 14.6% | 8.2% |
| 2011 | 7.7% | 13.1% | 6.6% |
| 2012 | 9.9% | 17.0% | 8.2% |
| 2013 | 8.9% | 17.1% | 7.3% |
| 2014 | 8.6% | 14.2% | 6.9% |
| 2015 | 9.8% | 15.9% | 7.8% |
| 2016 | 8.3% | 13.6% | 6.6% |
| 2017 | 10.5% | 17.1% | 8.5% |
| 2018 | 12.2% | 20.5% | 10.1% |
| 2019 | 18.4% | 31.2% | 14.9% |
| 2020 | 21.9% | 38.6% | 17.4% |
| 2021 | 25.5% | 46.6% | 19.7% |
| 2022 | 26.3% | 45.1% | 20.0% |
| 2023 | 20.0% | 33.2% | 16.8% |
| 2024 | 20.4% | 42.7% | 17.5% |
| 2025 | 21.4% | 43.7% | 17.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.